This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Peptide-drug conjugates offer targeted cancer delivery by linking tumor-homing peptides to cytotoxic drugs via specialized linkers, reducing off-target toxicity compared to chemotherapy.
Why it matters
Traditional chemotherapy damages healthy cells alongside cancer cells. PDCs aim to deliver the drug directly to tumors, potentially improving outcomes while reducing side effects.
The numbers in context
PDC components: targeting ligand + cytotoxic payload + linker; several in clinical trials; challenges: plasma stability, elimination, oral bioavailability
How the study worked
Narrative review of PDC design, delivery mechanisms, clinical applications, and limitations.
Who was studied
N/A (review of peptide-drug conjugate technology for cancer)
What this study cannot tell us
Narrative format without systematic search. Many PDCs discussed are still experimental. Clinical data are limited for most candidates.
Read the original research
Navigating cancer therapy: Harnessing the power of peptide-drug conjugates as precision delivery vehicles.
European journal of medicinal chemistry, 283, 117131
Citation
Sagar, Bulbul; Gupta, Sarthak; Verma, Sarvesh Kumar; Reddy, Y Veera Manohara; Shukla, Shefali. (2025). Navigating cancer therapy: Harnessing the power of peptide-drug conjugates as precision delivery vehicles.. European journal of medicinal chemistry, 283, 117131. https://doi.org/10.1016/j.ejmech.2024.117131